Pathogenesis and novel therapy for EBV-related B-cell lymphoma

DOI Web Site PubMed
  • SATO Ai
    Division of Hematology and Oncology, Department of Internal Medicine, Tokai University School of Medicine
  • YAMAKAWA Natsuko
    Division of Hematology and Oncology, Department of Internal Medicine, Tokai University School of Medicine Division of Hematology and Oncology, the Institute of Medical Sciences, Tokai University
  • KOTANI Ai
    Division of Hematology and Oncology, Department of Internal Medicine, Tokai University School of Medicine Division of Hematology and Oncology, the Institute of Medical Sciences, Tokai University PRESTO (Precursory Research for Embryonic Science and Technology), Japan Science and Technology Agency

Bibliographic Information

Other Title
  • EBV関連B細胞リンパ腫の病態と新規治療
  • EBV カンレン B サイボウ リンパシュ ノ ビョウタイ ト シンキ チリョウ

Search this article

Abstract

Epstein-Barr virus (EBV), a type of γ-herpes virus, is known to be a tumor virus. About 90% of adults were found to be persistently infected with EBV and this infection is responsible for Burkitt lymphoma (BL), extranodal NK/T cell lymphoma, Hodgkin lymphoma (HL), acquired Immune deficiency syndrome (AIDS)-associated lymphoma, and a portion of diffuse large B cell lymphomas (DLBCL). EBV-positive DLBCL in the elderly, a disease recognized in Japan, is described in the WHO classification as a new category of DLBCLs. Clinical studies of DLBCLs have since accumulated. We herein describe our clinicopathological study of EBV-positive DLBCL in the elderly in the rituximab era, and review EBV-positive B cell lymphoma cases. A potentially promising novel therapy for EBV-positive B cell lymphoma, anti-PD-1 antibody, is then introduced. Finally, we briefly discuss our unpublished study of EBV-positive B cell lymphoma and its microenvironment.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 57 (1), 3-8, 2016

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top